Staging of intestinal‐ and diffuse‐type gastric cancers with the OLGA and OLGIM staging systems. Issue 10 (6th October 2013)

• Record Type: Journal Article
• Authors: Cho, S.‐J.; Choi, I. J.; Kook, M.‐C.; Nam, B.‐H.; Kim, C. G.; Lee, J. Y.; Ryu, K. W.; Kim, Y.‐W.
• Is Part Of: Alimentary pharmacology & therapeutics. Volume 38:Issue 10(2013)
• Page Start: 1292
• Page End: 1302
• Publication Date: 2013-10-06
• Subjects: Digestive organs -- Diseases -- Treatment -- Periodicals; Digestive organs -- Effect of drugs on -- Periodicals; Gastrointestinal system -- Diseases -- Treatment -- Periodicals; Gastrointestinal system -- Effect of drugs on -- Periodicals; 615.73
• DOI: 10.1111/apt.12515
• Languages: English
• ISSNs: 0269-2813

Abstract

<abstract abstract-type="main" id="apt12515-abs-0001"> <title>Summary</title> <sec id="apt12515-sec-0001" sec-type="section"> <title>Background</title> <p>Operative link on gastritis assessment (OLGA) and Operative link on gastric intestinal metaplasia assessment (OLGIM) staging systems have been proposed for gastric cancer (GC) risk estimation.</p> </sec> <sec id="apt12515-sec-0002" sec-type="section"> <title>Aim</title> <p>To validate the OLGA and OLGIM staging systems in a region with high risk of GC.</p> </sec> <sec id="apt12515-sec-0003" sec-type="section"> <title>Methods</title> <p>This retrospective study included 474 GC patients and age‐ and sex‐matched health screening control persons in a cancer centre hospital. We classified gastritis patterns according to the OLGA and OLGIM systems using the histological database that a pathologist prospectively evaluated using the updated Sydney system. GC risk according to the OLGA and OLGIM stages was evaluated using logistic regression analysis.</p> </sec> <sec id="apt12515-sec-0004" sec-type="section"> <title>Results</title> <p>More GC patients had OLGA stages III–IV (46.2%) than controls (26.6%, <italic>P </italic><<italic> </italic>0.001), particularly among patients with intestinal‐type GCs (62.2%) compared with diffuse‐type GCs (30.9%). OLGA stages III and IV were significantly associated with increased risk of GC [odds ratios (ORs), 2.09; <italic>P </italic>=<italic> </italic>0.008 and 2.04; <italic>P </italic>=<italic> </italic>0.014 respectively] in multivariate analysis. The association was more significant for intestinal‐type (ORs, 4.76; <italic>P </italic>=<italic> </italic>0.001 and 4.19; <italic>P </italic>=<italic> </italic>0.002 respectively), but not diffuse‐type GC. OLGIM stages from I to IV were significantly associated with increased risk of both intestinal‐type (ORs, 3.64, 5.15, 7.89 and 13.20 respectively) and diffuse‐type GC (ORs, 1.84, 2.59, 5.08 and 6.32 respectively) with a significantly increasing trend.</p> </sec> <sec id="apt12515-sec-0005" sec-type="section"> <title>Conclusion</title> <p>As high OLGA and OLGIM stages are independent risk factors for gastric cancer, the staging systems may be useful for risk assessment in high‐risk regions, especially for intestinal‐type gastric cancer.</p> </sec> </abstract>